Prostate Adenocarcinoma

98

Pipeline Programs↗

17

Active Trials↗

42

Companies Involved↗

Prostate Adenocarcinoma is a moderately active landscape with 98 programs across 42 companies. The most active players are Syndax Pharmaceuticals, RECORDATI GROUP, Peregrine Pharmaceuticals. 41 therapies are approved with 17 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

70/100

Pipeline Velocity

25/100

Mech. Concentration

7/100

Completion Rate

82/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Syndax Pharmaceuticals

1 program

RECORDATI GROUP

1 program

Peregrine Pharmaceuticals

1 program

Daiichi Sankyo

1 program

Synta Pharmaceuticals Corp.

1 program

Imclone

1 program

Pipeline

Programs by Phase

Analysis

Modality Breakdown

84%

Small molecule

83 of 99 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 99 classified programs, each share of the total. Modality classified for 99% of 103 pipeline programs.

Analysis

Trial Status

30

clinical trials

Completed9 · 30%

Recruiting8 · 27%

Active, not recruiting6 · 20%

Not yet recruiting3 · 10%

Unknown status2 · 7%

Terminated2 · 7%

Clinical Trials

Trial Activity

30 trials

Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma

Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT07150715·107 enrolled

Phase 2 Study of High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for Intermediate and High Risk Localized Prostate Adenocarcinoma (HYDRA)

Recruiting·JJonsson Comprehensive Cancer Center·Preclinical·NCT04945642·52 enrolled

Prostate Specific Membrane Antigen (PSMA) or Fluciclovine (FACBC) PET/CT Site-Directed Therapy of OLigometASTatic Prostate Cancer (P-Flu-BLAST-PC): A Multicenter Study

Recruiting·UUniversity of Washington·Phase 2·NCT04175431·100 enrolled

INSPIRE: INnovative SABR for Prostate Cancer All IREland

Recruiting·CCancer Trials Ireland·Phase 2·NCT07552168·136 enrolled

Feasibility of MR-Informed Adaptive Marker-less SBRT in Patients With Bilateral Hip Prostheses Undergoing SBRT for Localized Prostate Cancer

Recruiting·UUniversity of Zurich·Preclinical·NCT07042256·13 enrolled

A Pilot Study of rhPSMA-PET MRI Imaging for the Detection of Clinically Actionable Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance

Recruiting·NNorthwestern University·Phase 1·NCT05852041·40 enrolled

The Phase III 'High Five Trial' Five Fraction Radiation For High-Risk Prostate Cancer

Recruiting·NRG Oncology·Phase 3·NCT05946213·1,209 enrolled

Prospective Single-Center Randomized Study Of Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound (HIFU)

Recruiting·CCase Comprehensive Cancer Center·Preclinical·NCT05610852·276 enrolled

Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies

Active, not recruiting·UUniversity Hospital, Rouen·N/A·NCT03611686·219 enrolled

PSMA PET Imaging of Recurrent Prostate Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03204123·1,171 enrolled

Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy

Active, not recruiting·JJonsson Comprehensive Cancer Center·Preclinical·NCT04624256·208 enrolled

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Active, not recruiting·NRG Oncology·Phase 3·NCT05050084·2,050 enrolled

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

Active, not recruiting·NRG Oncology·Phase 3·NCT04513717·2,753 enrolled

Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy

Active, not recruiting·NRG Oncology·Phase 3·NCT04134260·586 enrolled

Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma

Not yet recruiting·IInstituto do Cancer do Estado de São Paulo·Phase 1·NCT07316686·18 enrolled

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)